Review Article
OPEN
Pharmacological and Immunological Aspects of
Phage Therapy
Prasanth Manohar1, Ashok. J. Tamhankar2,3, Sebastian Leptihn4,5, Nachimuthu Ramesh1,Y
Abstract
Downloaded from https://journals.lww.com/imd by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3KirptPALrnDByZCQs6J7rHr0d191xjlhnNibrT7KDa9mGB14LP3U9g== on 01/09/2020
Bacteriophages, or viruses of microbes, when used as a medical strategy, might be able to solve the current crisis mankind faces with
the increasing number of pathogens being antibiotic-resistant, where chemical drugs seized to show any therapeutic effect. The socalled phage therapy may be one of the most promising alternatives to treat infections caused by antibiotic-resistant bacteria, which
are killed after infection by a phage. While phages that destroy the host by lysis are chosen for therapy, many pharmacological and
immunological aspects of phages as medicines have not been established so far. The immune system plays an important role in a
process called phage acceptance where both, innate and adaptive immune responses of the host are involved. However, not only
medical aspects but also social ones such as lacking public awareness or acceptance, and lack of structured regulatory guidelines
are challenges that have to be addressed in the near future to establish phage therapy as a reliable and safe alternative for the
treatment of infections. This review focuses on the unique pharmacological and immunological aspects of phages used in therapy.
Keywords: phage therapy; phage immune response; phage stability; bacteriophages; phage
divide. During the lytic cycle, the viral genome is replicated
immediately after infection without prior integration into the
host DNA.2 Lysogenic phages are able to enter a lytic phase, were
replication and assembly is followed by cell lysis of the bacterium.
Both lytic and lysogenic cycles produce a large amount of
progeny. As the aim of phage therapy (PT) is the clearance of
pathogens by killing the bacteria through lysis, phages in therapy
have to be lytic, as the integration of the viral DNA is undesired.
PT is not a new concept, described in the next paragraph; due to
multidrug-resistant bacteria it is re-emerging after a century to
kill pathogens as chemical drugs become ineffective.1
Hundred years into the discovery of phages; the first report of
antibacterial activity of phages was made by British bacteriologist
Ernest Hankin in 1896, who observed antibacterial activity in
water samples of the Ganges and the Yamuna rivers in India
against Vibrio cholerea, limiting the spread of cholera.1 A similar
phenomenon was observed 2 years later for Bacillus subtilis by
Russian bacteriologist, Gamaleya.3 It was Frederick Twort, a
medically trained bacteriologist from England, who suggested in
1914 that it may have been due to a virus.4 Felix d’Herelle, a
French-Canadian microbiologist who was the first to observe
clear zones without growth on bacterial lawns on agar plates,
which he called “plaques.” After a few years from his initial
finding, he proposed the name “bacteriophage,” literally the
“bacteria-eater.”5 Medical tests on human patients by d’Herelle
began in 1917, under the supervision of Prof. Victor-Henri
Hutinel at the Hospital des Enfants-Malades in Paris. He
demonstrated the efficacy of phages by administrating a solution
to a 12-year-old boy with severe dysentery. With the single
treatment, the patient made a complete recovery without any side
effects of the treatment.4 The same anti-dysentery phage was later
administrated to three more patients, all of which recovered
within 24 hours after the treatment.6 In 1923, the first tests were
performed in the United States, at the Baylor University of
Medicine in Texas. Here, successful medical trial results were
conducted and the physicians concluded the enormous possibilities to fight against bacterial infections by using phages.7 The
rapid rise of phages as therapeutics was rather quickly dampened
by the discovery of antibiotics and their introduction in the
Introduction
Bacteriophages (phages) are viral particles that infect and
replicate inside a bacterial cell with a high selectivity for a
particular host, that is, a bacterium the virus is able to infect.1 The
lytic (virulent) and the lysogenic (temperate) cycles are two
different viral reproduction mechanisms by which phages
replicate inside the host bacterium.2 The major difference
between the two cycles is the integration of the viral nucleic
acid into the bacterial genome during the lysogenic cycle, where
the phage genome is multiplied as the host continues to grow and
Editor: Stijn van der Veen
1
Antibiotic Resistance and Phage Therapy Laboratory, Department of Biomedical
Sciences, School of Biosciences and Technology, Vellore Institute of Technology
(VIT), Vellore 632014, Tamil Nadu, India, 2 Global Health, Health Systems and
Policy: Medicines-focusing Antibiotics, Department of Public Health Sciences,
Karolinska Institutet, Stockholm, Sweden, 3 Indian Initiative for Management of
Antibiotic resistance, Department of Environmental Medicine, Ruxmaniben
Deepchand Gardi Medical College, Ujjain, India, 4 Zhejiang University School of
Medicine, Zhejiang University-Edinburgh University (ZJU-UoE) Institute,
International Campus, Zhejiang University, Haining, Zhejiang 314400, China,
5
Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang
University School of Medicine, Hangzhou, China.
Y
Corresponding author: Nachimuthu Ramesh, SMV-203A, Antibiotic Resistance
and Phage Therapy Laboratory, Department of Biomedical Sciences, School of
Bio Sciences and Technology, Vellore Institute of Technology (VIT), Vellore
632014, Tamil Nadu, India. E-mail: drpnramesh@gmail.com
Author contributions: All authors PM, AJT, SL, and NR share equal contribution
in conception, design, analysis, and writing this review.
Funding: The author(s) received no specific funding for this work.
Conflicts of interest: The authors reported no conflicts of interest.
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NCND), where it is permissible to download and share the work provided it is
properly cited. The work cannot be changed in any way or used commercially
without permission from the journal.
Infectious Microbes & Diseases (2019) 1:2
Received: 6 October 2019 / Received in final form: 25 October 2019 / Accepted:
28 October 2019
http://dx.doi.org/10.1097/IM9.0000000000000013
34
Manohar et al., Infectious Microbes & Diseases (2019) 1:2
https://journals.lww.com/imd
subsequent years.7 Almost a century after the discovery of phages
and the first medical trials, the need for an alternative therapy
against infectious diseases is larger than ever, as antibiotic
resistance in bacteria has become a very serious human health
problem. Again, PT is gaining major attention all over the world.4
Studies had demonstrated the effectiveness of PT clinically. A
study by Mie˛ dzybrodzki et al. showed that the patients affected
by Staphylococcus aureus infections showed positive results
(either bacterial eradication or improvement in patient health) for
more than 36% of the patients and similar study also showed
recovery of patients with orthopaedic infections when phages are
administered orally or topically.16 Pharmacologically, bacteriophages may be considered to be selectively toxic antibacterial
agents.17 In that aspect, one of the advantages of using phages in
the clinic is that they are more targeted “drugs” than antibiotics,
which show a lesser degree of specificity towards bacteria, thus
also affecting the microbiome of the patient.17 In addition, the
discovery and the manipulation of the phage genetic elements are
easier with the technological tools available today. The
reconsideration of phages in therapy is due to the pharmacological advantages it has over the antibiotics. Pharmacokinetics of
phages, that is, the movement of a pharmacological element in the
body, demonstrates the benefit of using phages compared to
antibiotics, as they are specific to the target bacteria, meaning that
the phages would travel in the system only to adsorb onto the
specific host where they exhibit their action. The increase in
phage numbers observed in the presence of the specific host
bacteria cause no or minimal impact on non-targeted bacterial
strains and tissues.18 The specific nature of the bacteriophage
with a very narrow host range (being specific to one or a very few
strains of a bacterial species) also reduces the chances of a
possible secondary infection because it will not affect the other
non-target bacteria.18
Phages that have been administered via the oral route have
been observed in the bloodstream after about 2–4 hours postadministration.18 Prolonged presence of phages is monitored in
several cases but is found to be harmless.19 The number of phages
in the system correlates with the concentration of the host
bacteria, while full biological activity is observed only at the site
of infection. Phages are cleared by the normal activity of the
kidneys.20 The response of the body’s humoral and innate
immune system towards the phage varies depending on the type
of phage and the infection.21,22 In many cases, antibodies are
produced against the phage antigens, while in other cases, the
human body seems to be non-responsive with no antibody
production. This points towards a possible continuous presence,
and normal existence of such phages in the human system.22,23 If
phages are a natural component of the human microflora, phages
that enter a lytic stage but display lysogenic life cycle, might
increase the chance of the genomic integration of virulent genes.13
Pharmacokinetics in PT mainly deals with the dosage of phage
or phage cocktail required to reach the target site, infect the
pathogens and eradicate the bacterial infection. In general,
pharmacokinetics of any drug is important to understand the
systematic application of the compound. In case of topical
administration pharmacokinetics are ideal as the phages are
applied directly to the site of infections, for example, an open
wound.24,25 Here, the benefit is that the phages do not have to be
efficiently distributed throughout the body to reach the site of
infection, but are in addition able to penetrate biofilms, which
does not reduce absorption rates of phages to the surface of target
bacteria.4,26 This stands in stark contrast to the effectiveness of
chemical antibiotics which sometimes are unable to diffuse into
the chemically complex biofilms.26
Yet another clinical aspect of PT questions the possibility of
occurrence of phage resistant bacterial mutants by natural
selection (bacterial strains that are capable of becoming resistant
to bacteriophages that would infect them previously). Such an
Pharmacology of PT
Many reviews discuss the advantages and disadvantages of using
bacteriophages in therapy compared to antibiotics.8–10 Pharmacological aspects have to be mentioned even when complex
biological entities, such as bacterial viruses, are being used as
drugs. Pharmacodynamics, that is, the impact of the drug on
human body and pharmacokinetics, that is, the body’s reaction
towards drug, have to be discussed. Pharmacodynamic studies of
a drug refer to the toxicity as well as the side effects and possible
impact of the compound on non-target tissues. To define the
pharmacodynamic parameters of phages, it is necessary to study
the specificity of administrated phages during therapy. While PT
is being used as treatment in countries like Russia and Georgia,
no defined studies on the pharmacodynamic aspects of PT have
been performed to date.11 For its implementation especially in the
western world where antibiotics are still the main basis for
treatment of bacterial infections, it is necessary to overcome
possible legislative hurdles as well as to create public awareness
for PT.12
Phage’s used in therapy should not contain any genes that
encode virulence factors or protein toxins. A phage which is
found to be lysogenic, that is, has the ability to integrate into the
host’s genome, or contains toxic genes should not be used,
whereas lytic/virulent phages which cause lysis of the infected cell
can be considered for in vitro characterization and possible
subsequent therapeutic applications.13 A temperate phage
undergoing lysogeny (ie, the viral genome is integrated into
the bacterial host DNA where it gets multiplied by cell division of
the bacteria), might make the pathogen even more virulent as the
phage might carry genes delivering additional virulence factors,
or manipulating the host behavior, which does not eliminate the
pathogen from the infected individual but now requires yet
another specific and lytic phage to clear the infection.14,15 Thus, it
is absolutely necessary to find the most suitable phage for
treatment of an infection. Both in vitro and in vivo, preclinical
studies should find the phage fulfilling all criteria in order to be
considered for clinical trials and for the development into a
pharmaceutical product (Figure 1).14
Pharmacodynamic approaches from safe application of the
phage solution to killing titer and the so-called multiplicity of
infection (the number of phages per cell) are factors that need to
be carefully determined before using a phage as a treatment
strategy. Killing titre and multiplicity of infection are related to
the number of phages or phage cocktail that is required to infect
and kill all infection-causing bacterial cells completely. The safety
of a phage solution does not only concern the phage itself, such as
the absence of lysogeny or virulence genes, but also the liquid in
which the virus is contained. Here, no antigenic or pyrogenic
substances should be found that might be causing a direct or
indirect immune response, for example, bacterial components,
such as lipopolysaccharide. Another factor that is necessary to be
considered is that fact that during PT a large amount of bacterial
toxins (due to bacterial killing) may be released, which not only
affects the immune system but potentially impacts on the balance
of gut microbiota, a particular aspect which requires more
attention to improve PT.
35
Manohar et al., Infectious Microbes & Diseases (2019) 1:2
Infectious Microbes & Diseases
Figure 1. Future challenges for phage therapy.
could imply that the human immune system might not perceive
bacteriophages as a threat. Clear evidence has yet to be
established regarding an altered immune response towards
phages, including the clearance of microbial viruses by the
immune system.34 By simply comparing the size, bacteriophages
are larger than some eukaryotic viruses yet it is currently not clear
whether phages induce immune responses and how the
interaction with the immune system is.34 Simple immunization
of humans or animals, that is, the injection of a solution
containing phages produced phage antisera (antibodies against
phages) with low levels of antibodies present in previously nonimmunized humans/animals.36–38 It was also predicted that
“natural antibodies” may be present in the human body for Tlike bacteriophages due to the fact that they are commonly found
in the normal flora.38 In an experiment where mutant lambda
phages were introduced in the circulatory system, the phages
were removed by innate immune system and their circulating time
in blood was reduced, indicating that the immune response may
be triggered against the viral particles.39–40 There are not many
studies that could demonstrate the mechanisms of an anti-phage
cellular response, and also a controversy about how phages are
presented to the T-cells by Antigen-presenting cells (to initiate
antibody production and memory responses in future), passing
through epithelial barrier has not been solved, though several
hypotheses have been developed.41 Microorganisms such as
occurrence is expected in the long run when phages are constantly
in therapeutic use.27 This might be a resultant phenomenon
(occurrence of bacteriophage insensitive mutants) due to phage
inactivation or modification of phage receptor.28 However, while
the phage resistant mutants may arise in similar frequency in
which antibiotic-resistant superbugs occur, unlike antibiotics
(that are chemical entities not capable of self-modification)
phages are biological entities that have the capability to undergo
natural evolution and hence result in self-modification thereby
co-evolving with their specific host strain.29 The phage resistant
bacterial mutants arise after a lag, the length of which will define
“how common a bacterial species can exist before being a target
for the phages which co-evolves with the bacterial strain.”30
Immunologics of PT
Immunological responses of the human body as a result of
exposure to phages by ingestion or presence of phages in the
bloodstream are important aspects of PT. The immune system is a
complex network that reacts to the presence of foreign particles,
including microbial viruses. There is growing evidence demonstrating that bacteriophages are part of the healthy human
microbiota/virobiota and many studies are being conducted to
evaluate their role on the microbiome.31–35 Bacteriophages are
present in the human body in large numbers, which possibly
36
Manohar et al., Infectious Microbes & Diseases (2019) 1:2
https://journals.lww.com/imd
Figure 2. Pharmacological and immunological aspects of phage therapy.
in this case a drastic decrease in the C reactive protein, was
observed after phage administration although the infection was
not eliminated entirely.50 In another study, the activation of NFkappa B was found after allogeneic skin transplantation in mice
that diminished cellular infiltration.51 Surprisingly, even just the
presence of the coat protein gp12 from phage (T4-like), not the
entire phage, resulted in reduced levels of interleukin-1 and
interleukin-6 in serum of murine models.52 As phage particles
were also found not to produce inflammatory mediators nor
reactive oxygen species during therapy potentially make them
anti-inflammatory drug candidates.20,53,54 As phages are part of
the human microbiota, it is not surprising that they can act as
immunomodulatory and probiotics-like.20 Due to the effects
observed upon administration of phages as therapeutics, it
becomes clear that the success of phages in therapy depends not
only on its anti-bacterial but also on anti-inflammatory
characteristics as phages are good immunomodulators.55 Studies
also showed that phagocytosis of hosts’ cells are in some instances
influenced by phages while there is no evidence for phages to
activate phagocytosis. Interestingly, phages have been reported to
still be able to multiply inside the bacterial cells which have been
phagocytosed.55–57 Studies had also proven that intracellular
killing of pathogen/bacteria by phagocytes (granulocytes and
monocytes) is not influenced by the presence of phages.58
bacteriophages may interfere by a so far unknown mechanism
with the immune system of their hosts as studies suggest that
bacteriophages are beneficial and play a significant role in
maintenance of bacterial diversity in humans.42 While human PT
studies are being conducted for several years now, our knowledge
of the complex interaction of therapeutic phages with the immune
system has only marginally increased.43 A study by ŁusiakSzelachowska et al. provided information on the neutralization of
phages in patient sera receiving PT. The study concluded that the
mode of administration of phages is critical as one of the aims is
to reduce the anti-phage response of the patient during PT.44 In
more recent research, the ability of phages to interact with the
immune cells/mammalian cells is being extensively studied, also
encompassing phage immunogenicity and phage immunomodulation.45 In the vaccine development field, phages have been used
as vaccine vehicles. Here, it has been shown that phages can
stimulate innate and adaptive immune response; D’Apice et al.
demonstrated that bacteriophage fd virion particles are sensed by
dendritic cells as pathogens and both innate as well as the
adaptive immune system are activated.46 Another study by Smith
et al. found that bacteriophages are safe candidates for
immunization of patients with antibody-mediated immunodeficiency.47 Though the immunological applications of bacteriophages are enormous, such as the above-mentioned vaccine
development strategies,48 aspects of immunity need to be
considered for PT as well (Figure 2).
For PT to be successful, the administrated phages should reach
the infection site and multiply rapidly for eradication of
infection.49 The effectiveness of a medical therapy also depends
on anti-inflammatory properties. An anti-inflammatory response,
Immunocompetent and immunocompromised
patients
Over the recent years, the number of publications and research
projects in the field of PT and possible clinical or technological
37
Manohar et al., Infectious Microbes & Diseases (2019) 1:2
Infectious Microbes & Diseases
applications of phages has been constantly increasing. When
studying the application of phages and their interaction with their
hosts, a logical question to ask aims towards the understanding of
PT in immunocompromised patients.59 An immunocompromised individual displays a reduced ability to react towards
microbes as the immune system is inefficient in inducing an
immunogenic response against a foreign antigen.59 In contrast,
immunocompetent persons are individuals with a normal and
active immune response and such individuals are widely preferred
when understanding PT studies. Information regarding the
immune status of a person on recorded details in PT trials is
typically rare.59 However, therapeutic efficiency and safety
concerning usage of phages as antimicrobial agents in immunocompromised patients is highly important for the screening and
diagnosis of the efficacy of the treatment.60
Treating immunodeficient or -compromised patients would
allow scientists and physicians to gain exact data on the activity
and the efficacy of therapeutic phages, ultimately allowing to
standardize the dosage and the route of administration.59 The
clinical efficacy of PT in vivo is based on two parameters: The first
one is the lytic life cycle of the phage itself which results in the killing
of the host pathogenic bacteria by lysis. The second parameter is a
potential ability of the bacteriophage used in therapy to induce a
direct or an indirect immunogenic response by the organism
against the bacterial pathogen, or by being immunoregulatory.
Often, the lysed bacterial cell components trigger an immune
response even if intact bacterial cells are unable to elicit such an
immunogenic action.59 If prepared inadequately, phage preparations can contain compounds derived from bacterial cells such as
lipopolysaccharide,61 which results in the observation that some
phage lysates may possess immunostimulatory properties. However, this might be beneficial in some cases as an immunostimulatory effect could play in favor for clearing the infectious agent, as
well as when we consider the extensive suppression of immune
response in immunocompromised patients.59
Most of the in vivo testing of PT has been performed in
immunocompetent individuals, where the action of phages is
potentially acting synergistically with the immune system of the
individual. The therapeutic efficiency of phages may be different
when phages are administered to immunocompromised individuals. Studies conducted on mouse models that are immunocompetent revealed that lysis of bacteria by the phages are the main
reason for the therapeutic effect of the phage, while induction of
the immune response seemed to have no effect on the eradication
of microbes.62 When phage lysates were used to treat infections in
immunocompromised mice, lysis was again the reason for the
clearance of the pathogenic bacteria, while the potential
capability of the lysate to induce an immunogenic response
had no effect on the eradication of pathogen from the host.62
Considering the data obtained from immunodeficient patients
with antibiotic-resistant infections, we can conclude that PT is
highly valuable.63 Bacteriophages were successfully used for
therapy to cure bacterial infections in cancer patients and renal
allograft recipients.59,63 PT was also tested successfully in
immunodeficient mice models to cure S. aureus infections.64
These studies demonstrated that PT may be effective in patients
with autoimmune diseases as well.
Together with their hosts, phages can be found in the oral,
respiratory, gastrointestinal, and urinary tract, but also in the
blood serum, where no microbes are found in a healthy
individual.67 Large numbers of phages are present in the infant
intestines which decrease when the person grows up. Still, the
amount of bacteriophages in the human body is enormous which
might be providing a basis as biological stabilizers to the gut
microbiota.67 The most predominant phages in the human gut
belong to the family of Caudovirales (Myoviridae, Siphoviridae,
and Podoviridae), which is also the same family of phages used
for PT. Studies on healthy individuals proved the existence of
more than 1000 viral genotypes in the human gut. Most of these
are microbial viruses, including the family of Caudovirales and
prophages within bacterial genomes.65
An important aspect of phages in human body is their ability to
translocate within different tissues and organs.65,68 Studies have
shown that phages can move between the mucosal barriers and
blood, which could influence the immune response of the host.65
The influence on the immune system is an observation which is an
often overseen or disregarded aspect of bacteriophages, which
have been long thought to exist only to control the bacterial
population in the human gut.65
There is a considerable difference between the bacteriophages
observed in the human gut of a healthy individual compared to that
of an unhealthy person, with potential strong immunological
implications. Studies have suggested that the translocation of
phages in patients with gastrointestinal tract diseases may be higher
than that of healthy individuals because the permeability is higher
in the affected tissues during the disease.69 There is a disparity in
reports regarding the presence of phages in blood samples collected
during PT; one study reported the presence of phages in patient
blood during oral administration of T4 phages for the duration of
an entire month while a second study reported the absence of
phages in serum after oral administration of phages in healthy
volunteers.65,70 If phage destroys gut bacteria, they may inhibit the
translocation of these target bacteria into the patient tissue
influencing inflammatory factors.55 Phages can exhibit a strong
regulatory effect on gut immune cells; here, they possibly result in
down-regulation of the immune cell activities to reduce proinflammatory responses, but more detailed studies are required.55
Bacteriophages have been reported to be present in 45% of clinical
samples when bacterial infections were analyzed towards the
presence or the absence of microbial viruses. Considering this fact,
bacteriophages can have a strong interference during the clinical
practices. The role of bacteriophages in diagnosis is not very clear;
the interference of phage DNA with bacterial DNA during
molecular analysis might contaminate the patient samples. Patients
with intestinal diseases are found to have an increased number of
phage particles, possibly due to the induction of prophages.65,71
This is possibly due to the effect that some antibiotics which target
the bacterial DNA replication (eg, quinolone drugs), increase the
lysogenic phage particle numbers, while on the other hand, drugs
that are acting on the bacterial cell membrane will result in a lower
phage count due to lack of host bacteria.71
In the case of the inflammatory bowel disease (IBD), a decrease
in microbial diversity is considered as one of the more important
factors for the severity of the disease. Bacteriophages, which
might have a strong influence on bacterial populations in patients
with IBD should be investigated.72,41 A study suggested that the
abundance of bacteriophages can cause a reduced bacterial
diversity in the human gut that may lead to Crohn disease.73 In
contrast to this, another bowel disease, ulcerative colitis, was
found to have no correlation with virobiota itself, while the lysis
Bacteriophages in human – an important
component of the virobiome
Bacteriophages are the most abundant virobiota in the human
body especially in the gut where show the largest diversity.65,66
38
Manohar et al., Infectious Microbes & Diseases (2019) 1:2
https://journals.lww.com/imd
of bacterial cells due to bacteriophage infection is discussed as a
cause of the inflammation, which might be caused by the release
of bacterial toxins.65 A recent study suggested that the use of
bacteriophage cocktail could reduce the abundance of gut
microbiota which in turn might lead to an increased permeability
of intestinal membrane, which was discussed as a potential
reason for bowel disease.74 Again, as the underlying reason, the
release of bacterial toxins due to the lysis of the pathogen was
discussed, which can have a strong influence on microbial
diversity that potentially can lead to other symptomatic causes.
Contradictory to this observation, another study suggested the
important role of bacteriophages in maintaining human health
during IBD by influencing the microbial diversity,75 as they
observed a correlation of the diversity of phages with the diversity
of bacteria. Most of the studies were performed using murine
models which are of course not translatable to the clinical setting.
In general, phages have been found to outnumber the bacteria in
mucosal layer and the presence of phages in mucosa is believed to
be involved in the selection of commensals.76 Bacteriophages can
act as immunomodulatory elements by directly acting on immune
responses but the immunosuppressive role of phages in
controlling inflammatory and autoimmune response has not
been investigated conclusively.77 The future of PT looks
promising as there are many important studies being performed
at different parts of the world.78–86 The importance of phages in
anti-inflammatory and immunomodulatory activities will prove
to be advantageous for PT. Much data was gained from
investigating phages and their properties, while the importance of
bacteriophages in the human microbiome and immune system
remains to be fully elucidated. Therefore, further studies on the
role of bacteriophages in human health are required to fully
understand the complex and ancient relationship of the human
body with bacteria and their phages.
Clinical trials are currently being undertaken with Phase 1
trials shown no adverse reactions associated with the use of phage
cocktails, thus paving the way for Phase 2 clinical trials (eg, APS
Biocontrol Limited, Dundee, UK). The success of this work will
set a positive model for western medicine if Phase 3 trials can be
completed with a positive outcome. Wright et al. outlined that
success of PT greatly depends on the susceptibility of the target
bacteria present at the site of infection and accentuates the
importance of correctly identifying the pathogen before the phage
treatment.88,89
One concept which has received little attention in PT is their
use as “bacteriophage-based probiotics,” a novel, safe and
effective application.90 “Probiotic phages” eliminate potentially
pathogenic bacteria in the gut without interfering with the
healthy gut microflora, therefore preventing an illness. Because of
their specificity, phages can be used to specifically manipulate the
gut microflora, thereby providing protection against, for
example, diarrhea-causing microorganisms.
Phages can be used as powerful vehicles in the development of
vaccines; however, this application requires further research and
development. Phage-based vaccines may not only serve as a
preventive platform for the infectious microbial diseases but also
to combat against non-infectious diseases.91 Effect of phagebased vaccines is achieved through immunization which in turn
harvests the innate ability of the natural immune defense to fight
diseases. This could direct phage-based vaccine towards the
treatment of cancers, neurodegenerative disorders, drug addiction, and so on. Genetic engineering of phages can furthermore
improve the efficiency to deliver therapeutic cargoes to eukaryotic
hosts. Phage display permits the expression of wide variety of
antigens on the surface of phage particles which is a major
advantage in the field of vaccine development.
Removal of phages by the immune system is a major barrier for
bacteriophage delivery. Kim et al. constructed phages that were
conjugated with polyethylene glycol, which prolonged the blood
circulation time and decreased the level of T-Helper cells compared
to non-modified phages.92 In animal models, both unmodified
phages and polyethylene glycol-conjugated phages resulted in
rapid neutralization.92 When encapsulated into liposomes, phages
were able to efficiently reduce the number of Klebsiella pneumoniae in mice models,93 with increased retention time as compared
to the free phage.93 A promising avenue is the encapsulation of
phages including the construction of phages as micro- and nanoparticles in vesicles, emulsions, foams, nanogels, micelles, capsules,
membrane emulsification, and core-shell particles.94
Currently, PT focuses on comparably fast-dividing bacterial
species while for others PT has neither been explored nor
developed. Two examples are Mycobacterium africanum and
Mycobacterium leprae which exhibits very slow division times;
however, PT might be a promising solution for these
microbes.25,35,66,95 Several challenges lie ahead for the therapeutic application of phages such as the availability of phages against
specific host bacteria, difficulties in phage identification for rapid
and immediate therapy, elimination of bacterial toxins in the
phage products, response of body’s immune system to phages
such as neutralization, choice of delivery system to the host (mode
of administration and dosage), awareness in the public, and the
lack of regulatory guidelines. In conclusion, though several
therapeutic applications of bacteriophages are currently being
exploited, uncertainties in regulatory guidelines for phage
products along with the difficulties in patenting laws might
reduce the financial commitment of pharmaceutical companies. A
tremendous effort from governments, companies and applied as
Future Perspectives
PT is a field that will provide innumerable benefits to science in
general, but also to applied fields such as veterinary science,
and of course medicine in particular by offering a possible
solution to overcome the increasing problem of antibioticresistant pathogens. Combining antibiotic therapy and PT,
the use of phage cocktails, or the use of phage protein products
may be the most promising strategies for the treatment of
bacterial infections involving phage.83,85 Therefore, the focus
of PT should not lie on the discovery of phages alone, but on
investigating such strategies involving combinational therapies
or phage products. Phages have a tremendous potential in
reducing or eliminating the amount of infectious and resistant
bacteria in environments such as hospital wards (intensive
care unit) to reduce the risk of nosocomial infections. In
addition, the use of phages in reducing the number of multi- and
extreme drug-resistant bacteria in wastewater treatment plants
could help us to fight the global threat of the so-called
superbugs.
For the production of phages on an industrial scale, major
issues have not been adequately addressed such as the removal of
endotoxins and pyrogens, which are being released from the
disrupted cell during phage lysis. Merabishvilli et al. recently
described a protocol that employs an endotoxin removal kit
which provides sufficient purity for the phages for clinical trials. It
will be necessary to be able to scale up and optimize such
processes if more commercial entities move into PT in near
future.87
39
Manohar et al., Infectious Microbes & Diseases (2019) 1:2
Infectious Microbes & Diseases
well as academic research is a necessity translate PT from bench
to bedside.
[12]
Conclusions
[13]
Bacteriophage therapy is a promising but challenging field with
regulatory and technical hurdles that need to be overcome to
ensure its successful application in medicine. Technical challenges
connected with PT will require new strategies for addressing
phage manufacturing, phage delivery, and systemic side effects.
Phage treatment may be able to establish itself in western
medicine, predominantly in areas where it can also reduce large
medical costs. Antibacterial resistance has been recognized as a
global threat, with the World Health Organization calling it one
of the largest challenges of the 21st century and has resulted in a
Global Action Plan to address the problem. The whole world is
searching of solutions for keeping antibiotics useful for the
foreseeable future. PT has the potential to provide a solution
posed by multidrug-resistant bacterial pathogens. However, PT
may offer solutions in at least some areas but will not be able to
replace antibiotics completely. Considering that renewed research efforts are being made to exploit the use of PT, it may be
anticipated that over next 5–10 years PT may find its way in
clinical practices in life-threatening chronic bacterial infections
that show resistance towards currently available antibiotics.
Although bacteria acquire resistance against phages, this
resistance is not as problematic as resistance towards antibiotics,
as phages are biological entities that can adapt to resistant hosts.
Phage researchers are making relentless efforts to elucidate every
aspect of the science behind PT, ultimately contributing in saving
human lives.
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
Acknowledgments
The authors thank Dr. Vijaya Kumar (Department of Languages,
SSL, VIT, Vellore), Ms. Manali Kale (Department of Biotechnology, VIT, Vellore), and Ms. Reetu Ann Philip (Department of
Applied Microbiology, VIT, Vellore) for their critical remarks
during the preparation of this manuscript.
[26]
[27]
[28]
References
[29]
[1] Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy.
Antimicrob Agents Chemother 2001;45(3):649–659.
[2] Wu B, Wang R, Fane AG. The roles of bacteriophages in membranebased water and wastewater treatment processes: a review. Water Res
2017;110:120–132.
[3] Adhya S, Merril C. The road to phage therapy. Nat 2006;443:754–755.
[4] Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human
infections. Bacteriophage 2011;1(2):66–85.
[5] Duckworth DH. Who discovered bacteriophage? Bacteriol Rev 1976;40
(4):793–802.
[6] Setlow J, Randesi M, Adams J, Setlow B, Setlow P. Mutation and killing
of Escherichia coli expressing a cloned Bacillus subtilis gene whose
product alters DNA conformation. J Bacteriol 1992;174(9):2943–2950.
[7] Ho K. Bacteriophage therapy for bacterial infections: rekindling a
memory. Perspect Biol Med 2001;44(1):1–16.
[8] Adibi M, Hekmat AS, Mobasher N, et al. The effects of HPMC
concentration as an efficient pharmaceutical dosage form on phage
release pattern from gels. Trends in Pharmaceutical Sciences 2017;3
(1):19–24.
[9] Shlezinger M, Khalifa L, Houri-Haddad Y, et al. Phage therapy: a new
horizon in the antibacterial treatment of oral pathogens. Curr Top Med
Chem 2017;17(10):1199–1211.
[10] Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of
phage therapy. Future Microbiol 2013;8(6):769–783.
[11] Siatchikhina EN, Nabatnikov PA, Korovkin SA, Katlinsky AV, Ignatyev
GM. Selection criteria for bacterial strains and bacteriophages for the
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
40
formation of industrial collection of specifically lysing bacteria:
Klebsiellа, Escherichia, Proteus, Pseudomonas, Staphylococcus. Prophylaxis Diagnostics Release 2016;16(2):90–95.
Debarbieux L, Pirnay JP, Verbeken G, et al. A bacteriophage journey at
the European Medicines Agency. FEMS Microbiol Lett 2016;363(2):
fnv225.
Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage
therapy. Curr Pharma Biotechnol 2010;11(1):2–14.
Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr
Pharma Biotechnol 2010;11(1):28–47.
Curtright AJ, Abedon ST. Phage therapy: emergent property pharmacology. J Bioanal Biomed 2011;S6:002.
Kazmierczak Z, Górski A, Da˛browska K. Facing antibiotic resistance:
Staphylococcus aureus phages as a medical tool. Viruses 2014;6
(7):2551–2570.
Carlton RM, Noordman WH, Biswas B, De Meester ED, Loessner MJ.
Bacteriophage P100 for control of Listeria monocytogenes in foods:
genome sequence, bioinformatic analyses, oral toxicity study, and
application. Regul Toxicol Pharmacol 2005;43(3):301–312.
Debarbieux L, Leduc D, Maura D, et al. Bacteriophages can treat and
prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010;201
(7):1096–1104.
Pirnay JP, De Vos D, Verbeken G, et al. The phage therapy paradigm:
pret-a-porter or sur-mesure? Pharm Res 2011;28(4):934–937.
Górski A, Da˛browska K, Hodyra-Stefaniak K, Borysowski J, Mie˛ dzybrodzki R, Weber-Da˛browska B. Phages targeting infected tissues: novel
approach to phage therapy. Future Microbiol 2015;10(2):199–204.
Dabrowska K, Switała-Jelen K, Opolski A, Weber-Dabrowska B, Gorski
A. Bacteriophage penetration in vertebrates. J Appl Microbiol 2005;98
(1):7–13.
Leung CY, Weitz JS. Modeling the interactions between pathogenic
bacteria, bacteriophage and immune response. Bull Am Phys Soc 2016;
61.
Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential
solution for the antibiotic resistance crisis. J Infect Dev Ctries 2014;8
(2):129–136.
Drilling AJ, Ooi ML, Miljkovic D, et al. Long-term safety of topical
bacteriophage application to the frontal sinus region. Front Cell Infect
Microbiol 2017;7:49.
Da˛browska K. Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med Res Rev
2019;39(5):2000–2025.
Gilbert P, Rickard AH, McBain AJ. Biofilms and antimicrobial
resistance. Principles and practice of disinfection, preservation and
sterilization, 4th ed. Blackwell Publishing, Ltd, Fourth Edition, Malden,
Mass. 2004;128–138.
Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms.
Nat Rev Microbiol 2010;8(5):317–327.
Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance.
Adv Appl Microbiol 2010;70:217–248.
Waterbury JB, Valois FW. Resistance to co-occurring phages enables
marine Synechococcus communities to coexist with cyanophages
abundant in seawater. Appl Environ Microbiol 1993;59(10):3393–
3399.
Penadés JR, Chen J, Quiles-Puchalt, et al. Bacteriophage-mediated
spread of bacterial virulence genes. Current opinion in microbiology
2015;23:171–178.
Minot S, Sinha R, Chen J, et al. The human gut virome: inter-individual
variation and dynamic response to diet. Genome Res 2011;21(10):1616–
1625.
Virgin HW. The virome in mammalian physiology and disease. Cell
2014;157(1):142–150.
Brown-Jaque M, Muniesa M, Navarro F. Bacteriophages in clinical
samples can interfere with microbiological diagnostic tools. Sci Rep
2016;6:33000.
Navarro F, Muniesa M. Phages in the human body. Front Microbiol
2017;8:566.
Van Belleghem J, Da˛browska K, Vaneechoutte M, Barr J, Bollyky P.
Interactions between bacteriophage, bacteria, and the mammalian
immune system. Viruses 2019;11(1):10.
Gorski A, Miedzybrodzk R, Borysowski J. Lobocka M, Szybalski W,
et al. Chapter 2-“Phage as a modulator of immune responses: practical
implications for phage therapy. Advances in Virus Research. Bacteriophages Part B Sant Diego, CA: Academic Press; 2012;41–72. 83.
Bacon EJ, Richmond SJ, Wood DJ, Stirling P, Bevan BJ, Chalmers WS.
Serological detection of phage infection in Chlamydia psittaci recovered
from ducks. Vet Rec 2017;119(25-26):618–620.
Manohar et al., Infectious Microbes & Diseases (2019) 1:2
https://journals.lww.com/imd
[65] Łusiak-Szelachowska M, Weber-Da˛browska B, Jo
nczyk-Matysiak E,
Wojciechowska R, Górski A. Bacteriophages in the gastrointestinal tract
and their implications. Gut Pathog 2017;9(1):44.
[66] Cohen LJ. Phages trump bacteria in immune interactions. Sci Transl Med
2019;11(481):eaaw5331.
[67] Lim ES, Wang D, Holtz LR. The bacterial microbiome and
virome milestones of infant development. Trends Microbiol 2016;24
(10):801–810.
[68] Abeles SR, Pride DT. Molecular bases and role of viruses in the human
microbiome. J Mol Biol 2014;426(23):3892–3906.
[69] Górski A, Wa_zna E, Da˛browska BW, Da˛browska K,
Switała-Jele
n K,
Mie˛ dzybrodzki R. Bacteriophage translocation. Pathog Dis 2006;46
(3):313–319.
[70] Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli
phage T4 orally: a safety test of phage therapy. Antimicrob Agents
Chemother 2005;49(7):2874–2878.
[71] Fothergill JL, Mowat E, Walshaw MJ, Ledson MJ, James CE, Winstanley
C. Effect of antibiotic treatment on bacteriophage production by a cystic
fibrosis epidemic strain of Pseudomonas aeruginosa. Antimicrob Agents
Chemother 2011;55(1):426–428.
[72] Lucas López R, Grande Burgos MJ, Gálvez A, Pérez Pulido R.
The human gastrointestinal tract and oral microbiota in inflammatory
bowel disease: a state of the science review. APMIS 2017;125(1):3–10.
[73] Wagner J, Maksimovic J, Farries G, et al. Bacteriophages in gut samples
from pediatric Crohn’s disease patients: metagenomic analysis using 454
pyrosequencing. Inflamm Bowel Dis 2013;19(8):1598–1608.
[74] Tetz GV, Ruggles KV, Zhou H, Heguy A, Tsirigos A, Tetz V.
Bacteriophages as potential new mammalian pathogens. Sci Rep
2017;7(1):7043.
[75] Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ.
Healthy human gut phageome. Proc Natl Acad Sci 2016;113(37):10400–
10405.
[76] Barr JJ, Auro R, Furlan M, et al. Bacteriophage adhering to mucus
provide a non-host-derived immunity. Proc Natl Acad Sci 2013;110
(26):10771–10776.
[77] Górski A, Weber-Dabrowska B. The potential role of endogenous
bacteriophages in controlling invading pathogens. Cell Mol Life Sci
2005;62(5):511–519.
[78] Gelman D, Eisenkraft A, Chanishvili N, Nachman D, Glazer SC, Hazan
R. The history and promising future of phage therapy in the military
service. J Trauma Acute Care Surg 2018;85(1S):S18–S26.
[79] Bodier-Montagutelli E, Pardessus J, Dalloneau E, Fevre C, L’Hostis G,
Morello E et al. European Respiratory Journal. 2018; 52:PA2649
congress-2018. https://doi.org/10.1183/13993003.
[80] Akanda ZZ, Taha M, Abdelbary H. Current review—the rise of
bacteriophage as a unique therapeutic platform in treating periprosthetic joint infections. J Ortho Res 2018;36(4):1051–1060.
[81] Ofir G, Sorek R. Contemporary phage biology: from classic models to
new insights. Cell 2018;172(6):1260–1270.
[82] Gorski A, Jo
nczyk-Matysiak E, Mie˛ dzybrodzki R, et al. Phage therapy:
beyond antibacterial action. Front Med 2018;5:146.
[83] Manohar P, Nachimuthu R, Lopes BS. The therapeutic potential of
bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model. BMC microbial 2018;18(1):97.
[84] Manohar P, Tamhankar AJ, Lundborg CS, Ramesh N. Isolation,
characterization and in vivo efficacy of Escherichia phage myPSH1131.
PloS One 2018;13(10):e0206278.
[85] Manohar P, Stalsby Lundborg C, Tamhankar AJ, Nachimuthu R.
Therapeutic characterization and efficacy of bacteriophage cocktails
infecting Escherichia coli, Klebsiella pneumoniae and Enterobacter
species. Front Microbiol 2019;10:574.
[86] Manohar P, Ramesh N. Improved lyophilization conditions for longterm storage of bacteriophages. Sci Rep 2019;9(1):15242.
[87] Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled smallscale production of a well-defined bacteriophage cocktail for use in
human clinical trials. PloS One 2009;4(3):e4944.
[88] Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS,
Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans:
results of a phase I safety trial. J Wound Care 2009;18(6):237–243.
[89] Wright A, Hawkins CH, Änggård EE, Harper DR. A controlled clinical
trial of a therapeutic bacteriophage preparation in chronic otitis due to
antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of
efficacy. Clinical Otolaryngol 2009;34(4):349–357.
[90] Hume ME. Historic perspective: prebiotics, probiotics, and other
alternatives to antibiotics. Poultry Sci 2011;90(11):2663–2669.
[91] Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene
therapy and antibacterials. Trends Biotechnol 2006;24(5):212–218.
[38] Dabrowska K, Miernikiewicz P, Piotrowicz A, et al. Immunogenicity
studies of proteins forming the T4 phage head surface. J Virol 2014;88
(21):12551–12557.
[39] Geier MR, Trigg ME, Merril CR. Fate of bacteriophage lambda in nonimmune germ-free mice. Nat 1973;246(5430):221–223.
[40] Merril CR, Biswas B, Carlton R, et al. Long-circulating bacteriophage as
antibacterial agents. Proc Natl Acad Sci 1996;93(8):3188–3192.
[41] Krut O, Bekeredjian-Ding I. Contribution of the immune response to
phage therapy. J Immunol 2018;200(9):3037–3044.
[42] Letarov A, Kulikov E. The bacteriophages in human-and animal bodyassociated microbial communities. J Appl Microbiol 2009;107(1):1–3.
[43] Keen EC. Phage therapy: concept to cure. Frontiers in Microbiology
2012;3:238.
_
[44] Łusiak-Szelachowska M, Zaczek
M, Weber-Da˛browska B, et al. Phage
neutralization by sera of patients receiving phage therapy. Viral Immunol
2014;27(6):295–304.
[45] Nicastro J, Wong S, Khazaei Z, et al. Bacteriophage ApplicationsHistorical Perspective and Future Potential. Springer International
Publishing 2016.
[46] D’Apice L, Costa V, Sartorius R, Rovato M, Aprile M, De Berardinis P.
Stimulation of innate and adaptive immunity by using filamentous
bacteriophage fd targeted to DEC-205. J Immunol Res 2015;585078.
[47] Smith LL, Buckley R, Lugar P. Diagnostic immunization with
bacteriophage FX 174 in patients with common variable Immunodeficiency/Hypogammaglobulinemia. Front Immunol 2014;5:410.
[48] Criscuolo E, Spadini S, Lamanna J, Ferro M, Burioni R. Bacteriophages
and their immunological applications against infectious threats. J
Immunol Res 2017;3780697.
[49] Gorski A, Mie˛ dzybrodzki R, Weber-Da˛browska B, et al. Phage therapy:
combating infections with potential for evolving from merely a treatment
for complications to targeting diseases. Front Microbiol 2016;7:1515.
[50] Mie˛ dzybrodzki R, Fortuna W, Weber-Da˛browska B, Górski A. A
retrospective analysis of changes in inflammatory markers in patients
treated with bacterial viruses. Clin Exp Med 2009;9(4):303–312.
[51] Górski A, Kniotek M, Perkowska-Ptasi
nska A, et al. Bacteriophages and
transplantation tolerance. Transplant Proc 2006;38(1):331–333.
[52] Miernikiewicz P, Klopot A, Soluch R, et al. T4 phage tail adhesion Gp12
counteracts LPS-induced inflammation in vivo. Front Microbiol
2016;7:1112.
[53] Miernikiewicz P, Da˛browska K, Piotrowicz A, et al. T4 phage and its
head surface proteins do not stimulate inflammatory mediator production. PLoS One 2013;8(8):e71036.
[54] Borysowski J, Wierzbicki P, Kłosowska D, Korczak-Kowalska G,
Weber-Da˛browska B, Górski A. The effects of T4 and A3/R phage
preparations on whole-blood monocyte and neutrophil respiratory burts.
Viral Immunol 2010;23(5):541–544.
[55] Górski A, Mie˛ dzybrodzki R, Borysowski J, et al. Phage as a modulator of
immune response: practical implications for phage therapy. Adv Virus
Res 2012;83:41–71.
[56] Jo
nczyk-Matysiak E, Łusiak-Szelachowska M, Kłak M, et al. The effect
of bacteriophage preparations on intracellular killing of bacteria by
phagocytes. J Immun Res 2015;482863.
[57] Miernikiewicz P, Kłopot A, Soluch R, et al. T4 phage tail adhesin gp12
counteracts LPS-induced inflammation in vivo. Front Microbiol
2016;7:1112.
[58] Kurzepa-Skaradzinska A, Lusiak-Szelachowska M, Skaradzinski G, et al.
Influence of bacteriophage preparations on intracellular killing of
bacteria by human phagocytes in vitro. Viral Immunol 2013;26(2):150–
162.
[59] Borysowski J, Górski A. Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis 2008;12(5):466–471.
[60] Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage
therapy. Biotechnol Lett 2007;29(7):995–1003.
[61] Boratynski J, Syper D, Weber-Dabrowska B, Łusiak-Szelachowska MA,
Pozniak GR, Górski AN. Preparation of endotoxin-free bacteriophages.
Cell Mol Biol Lett 2004;9(2):253–259.
[62] Doss J, Culbertson K, Hahn D, Camacho J, Barekzi N. A review of phage
therapy against bacterial pathogens of aquatic and terrestrial organisms.
Viruses 2017;9(3):50.
[63] Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy for
infections in cancer patients. Clin Appl Immunol Rev 2001;1(3):131–
134.
[64] Zimecki M, Artym J, Kocie˛ ba M, Weber-Da˛browska B, Borysowski J,
Górski A. Prophylactic effect of bacteriophages on mice subjected to
chemotherapy-induced immunosuppression and bone marrow transplant upon infection with Staphylococcus aureus. Med Microbiol
Immunol 2010;199(2):71–79.
41
Manohar et al., Infectious Microbes & Diseases (2019) 1:2
Infectious Microbes & Diseases
[94] Malik DJ, Sokolov IJ, Vinner GV, et al. Formulation, stabilisation and
encapsulation of bacteriophage for phage therapy. Adv Colloid Interface
Sci 2017;249:100–133.
[95] Oliveira H, Sillankorva S, Merabishvili M, Kluskens LD, Azeredo J.
Unexploited opportunities for phage therapy. Frontiers Pharmacol
2015;6:180.
[92] Kim KP, Cha JD, Jang EH, et al. PEGylation of bacteriophages increases
blood circulation time and reduces T-helper type 1 immune response.
Microb Biotechnol 2008;1(3):247–257.
[93] Chadha P, Katare OP, Chhibber S. Liposome loaded phage cocktail:
Enhanced therapeutic potential in resolving Klebsiella pneumoniae
mediated burn wound infections. Burns 2017;43(7):1532–1543.
42